Itabuna

Researchers are investigating a treatment approach for patients hospitalized with community-acquired pneumonia (CAP), a condition with high rates of illness and death. This phase 3 trial compares therapeutic-dose heparin versus usual care pharmacological thromboprophylaxis to see if it improves patient outcomes. The study focuses on preventing complications caused by blood clots and inflammation that can worsen respiratory and organ function in CAP patients. Previous findings in COVID-19 pneumonia suggest heparin might reduce disease progression and mortality, but its effects in non-COVID-19 CAP are unknown. Participants will receive either therapeutic-dose heparin, preferably a low molecular weight heparin (LMWH) like enoxaparin, dalteparin, or tinzaparin, dosed by patient weight unless contraindicated. Intravenous unfractionated heparin (UFH) may be used instead, especially for those with kidney issues, with dosing adjusted to specific blood clotting targets. The trial is open-label and randomized, with adaptive rules to monitor progress. Usual care pharmacological thromboprophylaxis is the comparator. Treatment and monitoring occur during hospital admission, anticipated to last at least 72 hours after randomization. During the study, patients are assessed for survival at 30 days and monitored for complications related to CAP. Researchers collect clinical data including oxygen use, laboratory tests, and adverse events, tracking safety and effectiveness. The study excludes patients with active COVID-19, recent bleeding, contraindications to anticoagulation, or those receiving critical care interventions. Overall participation depends on hospital stay length and clinical status, with follow-up to evaluate the primary outcome of survival within a month.

Researchers are investigating breast and prostate cancer in patients treated through the Brazilian Unified Health System. The study focuses on understanding molecular changes in tumors, including genetic mutations that arise during cancer development, which can influence treatment responses and disease outcomes. It also aims to identify hereditary genetic syndromes to improve cancer follow-up and risk prediction. This effort supports the Brazilian Ministry of Health's National Precision Genomics and Health Program, Genomas Brasil, while collecting data on the population's ancestry. The project involves detailed genetic testing using whole exome and whole genome sequencing. For prostate and HER2-positive breast cancer, both somatic and germline whole exome sequencing will be conducted. For triple-negative breast cancer, somatic whole exome and germline whole genome sequencing will be analyzed. These tests are performed on tumor tissue and blood samples to map genetic variations linked to these cancers. Participants will provide tumor tissue and blood samples for genetic analysis. The study will characterize the complete somatic and germline exomes and genomes over a 12-month period. Researchers will collect clinical and genomic data to better understand cancer genetics and ancestry. Consent is required before inclusion, and the study monitors the genetic profiles of breast and prostate cancer patients to support precision medicine efforts in Brazil.